Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study
- 1 November 2018
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (11), e27363
- https://doi.org/10.1002/pbc.27363
Abstract
BackgroundRisk stratification is crucial to treatment decision-making in neuroblastoma. This study aimed to explore factors present at diagnosis affecting outcome in patients aged18 months with metastatic neuroblastoma and to develop a simple risk score for prognostication. ProcedureData were derived from the European high-risk neuroblastoma 1 (HR-NBL1)/International Society for Paediatric Oncology European Neuroblastoma (SIOPEN) trial with analysis restricted to patients aged 18 months with metastatic disease and treated prior to the introduction of immunotherapy. Primary endpoint was 5-year event-free survival (EFS). Prognostic factors assessed were sex, age, tumour MYCN amplification (MNA) status, serum lactate dehydrogenase (LDH)/ferritin, primary tumour and metastatic sites. Factors significant in univariate analysis were incorporated into a multi-variable model and an additive scoring system developed based on estimated log-cumulative hazard ratios. ResultsThe cohort included 1053 patients with median follow-up 5.5years and EFS 271%. In univariate analyses, age; serum LDH and ferritin; involvement of bone marrow, bone, liver or lung; and >1 metastatic system/compartment were associated with worse EFS. Tumour MNA was not associated with worse EFS. A multi-variable model and risk score incorporating age (>5 years, 2 points), serum LDH (>1250U/L, 1 point) and number of metastatic systems (>1, 2 points) were developed. EFS was significantly correlated with risk score: EFS 52 +/- 9% for score=0versus 6 +/- 3% for score=5 (P<0.0001). ConclusionsA simple score can identify an ultra-high risk (UHR) cohort (score=5) comprising 8% of patients with 5-year EFS<10%. These patients appear not to benefit from induction therapy and could potentially be directed earlier to alternative experimental therapies in future trials.Keywords
Funding Information
- European Commission 5th Framework Grant
- St Anna Kinderkrebsforschung
This publication has 34 references indexed in Scilit:
- Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trialsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group databaseEuropean Journal Of Cancer, 2016
- MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Metastatic Neuroblastoma Confined to Distant Lymph Nodes (stage 4N) Predicts Outcome in Patients With Stage 4 Disease: A Study From the International Neuroblastoma Risk Group DatabaseJournal of Clinical Oncology, 2014
- Neuroblastoma mRNAs Predict Outcome in Children With Stage 4 Neuroblastoma: A European HR-NBL1/SIOPEN StudyJournal of Clinical Oncology, 2014
- Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology GroupJournal of Nuclear Medicine, 2013
- Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG projectBritish Journal of Cancer, 2012
- The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) projectPediatric Blood & Cancer, 2008
- NeuroblastomaThe Lancet, 2007